A First-in-Human Phase 1 Study of SPT-300, a First-in-Class Orally Bioavailable Prodrug of the NeurosteroidAllopregnanolone That is Absorbed via the Lymphatic System
Thursday, December 19, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a Phase 1 study of SPT-300, an innovative orally bioavailable prodrug of the neurosteroid allopregnanolone. This drug is notable for its absorption via the lymphatic system, marking a potential breakthrough in neurosteroid therapies. The study aims to evaluate the safety and efficacy of this novel treatment.
Market Sentiment Analysis
POSITIVE FACTORS
SPT-300 is a first-in-class neurosteroid prodrug.
The study represents a significant advancement in drug delivery via the lymphatic system.
Potential for novel treatment options in neurosteroid therapies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - December 19, 2024
A First-in-Human Phase 1 Study of SPT-300, a First-in-Class Orally Bioavailable Prodrug of the NeurosteroidAllopregnanolone That is Absorbed via the Lymphatic System
Frequently Asked Questions
What is SPT-300?
SPT-300 is a first-in-class orally bioavailable prodrug of the neurosteroid allopregnanolone.
How is SPT-300 absorbed?
SPT-300 is absorbed via the lymphatic system, which is a novel delivery method.
What phase is the SPT-300 study in?
The study of SPT-300 is currently in Phase 1.
What does the Phase 1 study aim to evaluate?
The Phase 1 study aims to evaluate the safety and efficacy of SPT-300.